48 participants
Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-08-28
- Start Date:
- 2019-06-27
- Completion:
- 2027-07-01
Conditions
- Central Nervous System Lymphoma
- Secondary Central Nervous System Lymphoma
Interventions
- DRUG
No Results Yet